A citation-based method for searching scientific literature


List of co-cited articles
33 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, Romel Somwar, Jennifer F Kherani, Jieun Son, Arrien A Bertram, Monika A Davare, Eric Gladstone, Elena V Ivanova,[...]. Clin Cancer Res 2021
35
66

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
V Subbiah, T Shen, S S Terzyan, X Liu, X Hu, K P Patel, M Hu, M Cabanillas, A Behrang, F Meric-Bernstam,[...]. Ann Oncol 2021
52
66

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
J J Lin, S V Liu, C E McCoach, V W Zhu, A C Tan, S Yoda, J Peterson, A Do, K Prutisto-Chang, I Dagogo-Jack,[...]. Ann Oncol 2020
58
66

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S Baik, Robert C Doebele, Philippe A Cassier, Gilberto Lopes, Daniel S W Tan,[...]. Lancet Oncol 2021
49
50

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions.
Janice Kim, Diana Bradford, Erin Larkins, Lee H Pai-Scherf, Somak Chatterjee, Pallavi S Mishra-Kalyani, Emily Wearne, Whitney S Helms, Amal Ayyoub, Youwei Bi,[...]. Clin Cancer Res 2021
14
50

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
397
50

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
186
50

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
89
50

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Sarah K Nelson-Taylor, Anh T Le, Minjae Yoo, Laura Schubert, Katie M Mishall, Andrea Doak, Marileila Varella-Garcia, Aik-Choon Tan, Robert C Doebele. Mol Cancer Ther 2017
46
50

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
33

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
449
33

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
C Belli, F Penault-Llorca, M Ladanyi, N Normanno, J-Y Scoazec, L Lacroix, J S Reis-Filho, V Subbiah, J F Gainor, V Endris,[...]. Ann Oncol 2021
28
33

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2021
80
33

RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
Teodora Radonic, W R R Geurts-Giele, Kris G Samsom, Guido M J M Roemen, Jan H von der Thüsen, Erik Thunnissen, Isabelle C Meijssen, Hein F B M Sleddens, Winand N M Dinjens, Mirjam C Boelens,[...]. J Thorac Oncol 2021
14
33

State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric-Bernstam. J Clin Oncol 2020
76
33

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
V Subbiah, T Shen, M Tetzlaff, A Weissferdt, L A Byers, T Cascone, A Behrang, F Meric-Bernstam, B H M Mooers, S M Rothenberg,[...]. Ann Oncol 2021
8
33

Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation.
Carina Heydt, Christina B Wölwer, Oscar Velazquez Camacho, Svenja Wagener-Ryczek, Roberto Pappesch, Janna Siemanowski, Jan Rehker, Florian Haller, Abbas Agaimy, Karl Worm,[...]. BMC Med Genomics 2021
18
33

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
221
33

Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Roberto Ferrara, Nathalie Auger, Edouard Auclin, Benjamin Besse. J Thorac Oncol 2018
92
33

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
Christian Rolfo, Philip Mack, Giorgio V Scagliotti, Charu Aggarwal, Maria E Arcila, Fabrice Barlesi, Trever Bivona, Maximilian Diehn, Caroline Dive, Rafal Dziadziuszko,[...]. J Thorac Oncol 2021
64
33

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Shumei Kato, Vivek Subbiah, Erica Marchlik, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock. Clin Cancer Res 2017
113
33

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
615
33

Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.
Sara Fancelli, Enrico Caliman, Francesca Mazzoni, Marco Brugia, Francesca Castiglione, Luca Voltolini, Serena Pillozzi, Lorenzo Antonuzzo. Cancers (Basel) 2021
8
33

Precision therapy for RET-altered cancers with RET inhibitors.
Kyaw Z Thein, Vamsidhar Velcheti, Blaine H M Mooers, Jie Wu, Vivek Subbiah. Trends Cancer 2021
10
33

RET fusions in solid tumors.
Andrew Y Li, Michael G McCusker, Alessandro Russo, Katherine A Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo, Christian Rolfo. Cancer Treat Rev 2019
76
33

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Alexander Drilon, Zishuo I Hu, Gillianne G Y Lai, Daniel S W Tan. Nat Rev Clin Oncol 2018
134
33

Direct interactions among Ret, GDNF and GFRalpha1 molecules reveal new insights into the assembly of a functional three-protein complex.
Angela Amoresano, Mariarosaria Incoronato, Gianluca Monti, Piero Pucci, Vittorio de Franciscis, Laura Cerchia. Cell Signal 2005
38
33


Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, Christoph Weinlinger, Amanda Tufman, Aurélie Swalduz, Kristina Lamberg, Sayed M S Hashemi, Florian Huemer, Anders Vikström,[...]. Ther Adv Med Oncol 2021
4
50

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
A Drilon, I Bergagnini, L Delasos, J Sabari, K M Woo, A Plodkowski, L Wang, M D Hellmann, P Joubert, C S Sima,[...]. Ann Oncol 2016
63
33

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
33

Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
Lisa M Hess, Yimei Han, Yajun Emily Zhu, Naleen Raj Bhandari, Anthony Sireci. BMC Cancer 2021
8
33

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
203
33

Endometrial cancer risk and survival by tumor MMR status.
Christina M Nagle, Tracy A O'Mara, Yen Tan, Daniel D Buchanan, Andreas Obermair, Penny Blomfield, Michael A Quinn, Penelope M Webb, Amanda B Spurdle. J Gynecol Oncol 2018
23
16

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Alain Ravaud, Christelle de la Fouchardière, Philippe Caron, Adelaïde Doussau, Christine Do Cao, Julien Asselineau, Patrice Rodien, Damien Pouessel, Patricia Nicolli-Sire, Marc Klein,[...]. Eur J Cancer 2017
63
16

Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation.
Hidewaki Nakagawa, Janet C Lockman, Wendy L Frankel, Heather Hampel, Kelle Steenblock, Lawrence J Burgart, Stephen N Thibodeau, Albert de la Chapelle. Cancer Res 2004
116
16

Landscape of Microsatellite Instability Across 39 Cancer Types.
Russell Bonneville, Melanie A Krook, Esko A Kautto, Jharna Miya, Michele R Wing, Hui-Zi Chen, Julie W Reeser, Lianbo Yu, Sameek Roychowdhury. JCO Precis Oncol 2017
412
16

Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome Profiling.
Naveen Ravi, Minjun Yang, Sigurdur Gretarsson, Caroline Jansson, Nektaria Mylona, Saskia R Sydow, Eleanor L Woodward, Lars Ekblad, Johan Wennerberg, Kajsa Paulsson. Cancers (Basel) 2019
20
16

Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
Eleonora Molinaro, Cristina Romei, Agnese Biagini, Elena Sabini, Laura Agate, Salvatore Mazzeo, Gabriele Materazzi, Stefano Sellari-Franceschini, Alessandro Ribechini, Liborio Torregrossa,[...]. Nat Rev Endocrinol 2017
199
16

Sorafenib in metastatic thyroid cancer.
Jaume Capdevila, Lara Iglesias, Irene Halperin, Angel Segura, Javier Martínez-Trufero, Maria Ángeles Vaz, Jesús Corral, Gabriel Obiols, Enrique Grande, Juan Jose Grau,[...]. Endocr Relat Cancer 2012
83
16

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
16

Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers.
Luke K Genutis, Jerneja Tomsic, Ralf A Bundschuh, Pamela L Brock, Michelle D Williams, Sameek Roychowdhury, Julie W Reeser, Wendy L Frankel, Mohammed Alsomali, Mark J Routbort,[...]. Thyroid 2019
19
16


Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Wassim Abida, Michael L Cheng, Joshua Armenia, Sumit Middha, Karen A Autio, Hebert Alberto Vargas, Dana Rathkopf, Michael J Morris, Daniel C Danila, Susan F Slovin,[...]. JAMA Oncol 2019
265
16

Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades.
Mischa de Ridder, Els Nieveen van Dijkum, Anton Engelsman, Ellen Kapiteijn, Heinz-Josef Klümpen, Coen R N Rasch. Eur J Endocrinol 2020
8
16

PD-1/PD-L1 inhibitors.
Joel Sunshine, Janis M Taube. Curr Opin Pharmacol 2015
341
16

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Eran Brauner, Viswanath Gunda, Pierre Vanden Borre, David Zurakowski, Yon Seon Kim, Kate Virginia Dennett, Salma Amin, Gordon James Freeman, Sareh Parangi. Oncotarget 2016
57
16

Absence of microsatellite instability in thyroid carcinomas.
F Vermiglio, M Schlumberger, V Lazar, I Lefreré, B Bressac. Eur J Cancer 1995
15
16

Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2.
S J Scherer, C Welter, K D Zang, S Dooley. Biochem Biophys Res Commun 1996
70
16

Thyroid cancer in Denmark 1943-2008, before and after iodine supplementation.
M Blomberg, U Feldt-Rasmussen, K K Andersen, S K Kjaer. Int J Cancer 2012
75
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.